Skip to main content

Market Overview

KemPharm Shares Trade Higher After FDA Approval For Azstarys In ADHD

  • The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.
  • ADHD is a neurobehavioral disorder of childhood that makes it difficult for a person to pay attention and control impulsive behaviors.
  • AZSTARYS consists of serdexmethylphenidate, KemPharm's prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
  • Azstarys will be commercially available in the U.S. as early as the second half of 2021.
  • Price Action: KMPH shares soared 78.7% at $16.85 in premarket trading on the last check Wednesday.

Related Articles (KMPH)

View Comments and Join the Discussion!

Posted-In: ADHDBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at